Chapter 3: Pharmacodynamics — Module 1: The Receptor Concept, Binding Kinetics and Drug-Receptor Interaction
1. Which of the following drugs produces its antiplatelet effect through irreversible covalent modification of its molecular target?
A) Clopidogrel, which reversibly inhibits the P2Y12 ADP receptor on platelet membranes through its active thiol metabolite
B) Ticagrelor, which reversibly binds the P2Y12 receptor without requiring metabolic activation, producing competitive antagonism at the ADP binding site
C) Abciximab, which reversibly blocks the glycoprotein IIb/IIIa fibrinogen receptor on activated platelets through high-affinity non-covalent binding
D) Aspirin, which irreversibly acetylates the active-site serine residue of cyclooxygenase-1 (COX-1) in platelets, permanently inactivating the enzyme for the life of the platelet (7-10 days) because platelets lack the nucleus required to synthesize new COX-1
E) Dipyridamole, which inhibits phosphodiesterase and adenosine uptake to elevate platelet cyclic adenosine monophosphate (cAMP), producing reversible inhibition of platelet aggregation through PKA-mediated signaling
ANSWER: D
Rationale:
Aspirin is the classic example of irreversible covalent pharmacology at a clinically important target. It transfers an acetyl group from its own ester linkage onto the hydroxyl group of a specific serine residue (Ser530 in human COX-1) at the active site of cyclooxygenase. This covalent acetylation permanently blocks the channel through which arachidonic acid must pass to reach the catalytic site, inactivating the enzyme irreversibly. Because platelets are anucleate cells incapable of synthesizing new proteins, COX-1 activity is abolished for the entire remaining lifespan of the platelet -- approximately 7-10 days. This is why aspirin's antiplatelet effect persists long after the drug is cleared from plasma and why aspirin is dosed once daily despite a plasma half-life of only 15-20 minutes. The antiplatelet effect recovers only as new platelets are generated from megakaryocytes.
Option A: Option A is incorrect -- clopidogrel's active metabolite does form a covalent bond with the P2Y12 receptor (at a cysteine residue), but the stem asks for the drug acting through irreversible covalent target modification, and aspirin is the answer; clopidogrel is also irreversible but the question specifically identifies aspirin's mechanism.
Option B: Option B is incorrect -- ticagrelor binds reversibly to P2Y12; it is a direct-acting, non-thienopyridine antiplatelet agent that does not require metabolic activation and does not form a covalent bond.
Option C: Option C is incorrect -- abciximab is a monoclonal antibody Fab fragment that binds glycoprotein IIb/IIIa with high affinity but through non-covalent interactions; the binding is reversible, though functionally long-lasting.
Option E: Option E is incorrect -- dipyridamole acts through reversible enzyme inhibition of phosphodiesterase and reversible inhibition of adenosine transporters; no covalent modification occurs.
2. The equilibrium dissociation constant Kd is a direct measure of which pharmacological property?
A) The binding affinity of a drug for its receptor -- specifically the concentration at which 50% of receptors are occupied at equilibrium; a low Kd indicates high affinity (tight binding), a high Kd indicates low affinity (weak binding)
B) The maximum biological effect a drug can produce, regardless of the concentration applied, reflecting the drug's intrinsic efficacy at its receptor
C) The concentration of drug producing 50% of its maximum biological effect in a functional assay, incorporating both receptor binding affinity and the efficiency of stimulus-response coupling
D) The intrinsic efficacy of a drug -- its capacity to activate a receptor once bound, distinguishing full agonists from partial agonists and antagonists
E) The rate at which a drug dissociates from its receptor independent of the association rate, determining the duration of receptor occupancy after a single binding event
ANSWER: A
Rationale:
The equilibrium dissociation constant (Kd) is a thermodynamic measure of binding affinity derived from the law of mass action. At equilibrium, Kd equals the ratio of the dissociation rate constant (koff) to the association rate constant (kon). Importantly, Kd represents the concentration of free drug at which exactly 50% of receptor binding sites are occupied at equilibrium -- it is a receptor occupancy parameter, not a functional pharmacodynamic parameter. A drug with a Kd of 1 nM occupies 50% of available receptors when the free drug concentration is 1 nM; a drug with a Kd of 1 micromolar requires a 1000-fold higher concentration to achieve the same fractional occupancy. The clinical distinction between Kd and EC50 (the concentration producing 50% of maximum effect) is fundamental: Kd measures binding, while EC50 measures functional effect. For drugs with receptor reserve, EC50 is lower than Kd because maximum effect is achieved before maximum receptor occupancy.
Option B: Option B is incorrect -- maximum biological effect is Emax, a pharmacodynamic parameter reflecting intrinsic efficacy; it is independent of Kd.
Option C: Option C is incorrect -- the concentration producing 50% of maximum effect is EC50, not Kd; EC50 incorporates receptor binding affinity and stimulus-response coupling efficiency and is lower than Kd when receptor reserve is present.
Option D: Option D is incorrect -- intrinsic efficacy is a separate pharmacodynamic concept describing a drug's capacity to activate its receptor once bound; a drug can have high affinity (low Kd) and zero intrinsic efficacy (competitive antagonist).
Option E: Option E is incorrect -- the dissociation rate constant koff determines how rapidly a drug leaves its receptor, but Kd is the ratio of koff to kon at equilibrium and represents affinity, not simply the dissociation rate alone.
3. Phenoxybenzamine is classified as which type of receptor antagonist at alpha-adrenergic receptors?
A) Competitive reversible antagonist, because it occupies the same binding site as norepinephrine and can be displaced by increasing norepinephrine concentrations
B) Allosteric antagonist, because it binds a site distinct from the norepinephrine-binding domain and reduces receptor affinity for norepinephrine without competing directly for the orthosteric site
C) Partial agonist, because it produces weak alpha-adrenergic activation before blocking subsequent receptor activation by norepinephrine
D) Inverse agonist, because it suppresses constitutive alpha-adrenergic receptor activity below baseline levels through its covalent receptor modification
E) Irreversible antagonist, because it forms a covalent bond with the alpha-adrenergic receptor that cannot be overcome by increasing agonist concentration; the maximum effect achievable by norepinephrine (Emax) is progressively reduced as more receptors are permanently inactivated, which is the pharmacological basis for Furchgott's method of quantifying receptor reserve
ANSWER: E
Rationale:
Phenoxybenzamine is a haloalkylamine compound that undergoes intramolecular cyclization to form a reactive ethylenimonium ion, which then alkylates nucleophilic residues (primarily cysteine and possibly other residues) at or near the orthosteric binding site of alpha-adrenergic receptors. This covalent modification produces irreversible blockade -- receptor function is permanently abolished for that individual receptor molecule, and the block cannot be overcome by increasing agonist concentration. This is the pharmacodynamic signature of irreversible antagonism: it reduces Emax rather than simply shifting the agonist dose-response curve to the right. Furchgott exploited this property to quantify receptor reserve in functional tissues -- by treating tissue with progressively increasing concentrations of phenoxybenzamine to inactivate increasing fractions of receptors, the relationship between receptor occupancy and functional response can be mathematically dissected, revealing the spare receptor fraction. Clinically, phenoxybenzamine is used in pheochromocytoma management, where sustained alpha-blockade is required during tumor surgery.
Option A: Option A is incorrect -- competitive reversible antagonists shift the agonist dose-response curve rightward without reducing Emax; phenoxybenzamine reduces Emax, the hallmark of irreversible blockade.
Option B: Option B is incorrect -- phenoxybenzamine acts at or near the orthosteric site, not at an allosteric site; its mechanism is covalent inactivation, not allosteric modulation.
Option C: Option C is incorrect -- phenoxybenzamine has no agonist activity; it is a pure antagonist with no capacity to activate alpha-adrenergic receptors.
Option D: Option D is incorrect -- inverse agonism refers to suppression of constitutive (ligand-independent) receptor activity; phenoxybenzamine does not selectively suppress constitutive activity; it irreversibly inactivates the receptor entirely.
4. Furchgott's spare receptor (receptor reserve) concept was originally demonstrated in which tissue, and what was the finding?
A) In cardiac muscle, where less than 5% beta1-receptor occupancy was sufficient to produce maximum inotropic response, demonstrating that the heart maintains a large receptor reserve for adrenergic stimulation
B) In vascular smooth muscle, where full alpha1-adrenergic receptor occupancy was required to produce maximum vasoconstriction, demonstrating the absence of receptor reserve in vascular tissue
C) In guinea pig ileum, where only 1-2% occupancy of histamine receptors was sufficient to produce maximum contractile response, demonstrating that the vast majority of histamine receptors in this tissue are spare receptors not required for maximum effect
D) In the neuromuscular junction, where 90% nicotinic receptor occupancy was required before detectable muscle contraction could be observed, demonstrating an unusually high threshold for neuromuscular transmission
E) In central opioid pathways, where mu-receptor occupancy greater than 70% was necessary for maximum analgesia, demonstrating that receptor reserve in pain pathways is minimal compared to peripheral tissues
ANSWER: C
Rationale:
Furchgott's original receptor reserve experiments were conducted in guinea pig ileum using histamine as the agonist. By treating the tissue with progressively increasing concentrations of the irreversible antagonist dibenamine (related to phenoxybenzamine) to permanently inactivate increasing fractions of histamine receptors, Furchgott demonstrated that maximum contractile response was maintained even when the vast majority of receptors had been irreversibly blocked. The data showed that only approximately 1-2% of the total histamine receptor population needed to be occupied to produce maximum contraction -- the remaining 98-99% of receptors were spare receptors that contributed no additional effect when occupied. This finding revolutionized receptor pharmacology by demonstrating that the relationship between receptor occupancy and biological response is not linear and that Emax can be achieved at sub-saturating agonist concentrations. The receptor reserve serves as a safety margin -- it ensures robust physiological responses even when receptor density declines through disease or drug-induced downregulation.
Option A: Option A is incorrect -- the Furchgott demonstration was in guinea pig ileum with histamine, not in cardiac muscle with beta1 receptors; the cardiac figure cited is inaccurate.
Option B: Option B is incorrect -- full receptor occupancy being required for maximum response would indicate the absence of receptor reserve, which is the opposite of Furchgott's finding.
Option D: Option D is incorrect -- the neuromuscular junction does have significant receptor reserve (only a fraction of nicotinic receptors need be occupied for full twitch tension), but this is not the tissue in which Furchgott made his original observations.
Option E: Option E is incorrect -- opioid pathways do have receptor reserve, but this is not Furchgott's original experimental demonstration.
5. A radioligand binding saturation assay directly measures which two parameters?
A) EC50 (potency) and Emax (efficacy) -- the two pharmacodynamic parameters needed to construct a functional concentration-effect curve for a drug at its receptor
B) Bmax (total receptor density) and Kd (receptor affinity for the radioligand) -- providing a direct measure of how many receptors are present in a tissue preparation and how tightly the radioligand binds to them
C) kon (association rate) and koff (dissociation rate) -- the kinetic parameters that determine how rapidly drug-receptor equilibrium is established and how long receptor occupancy persists
D) Intrinsic efficacy and functional potency -- allowing discrimination between agonists, partial agonists, and antagonists based on their binding profiles alone
E) Receptor reserve and Hill coefficient -- quantifying cooperativity and the size of the spare receptor pool in a single experimental assay
ANSWER: B
Rationale:
A radioligand saturation assay is a direct receptor binding experiment in which a radiolabeled drug (the radioligand) is incubated with a tissue or membrane preparation at multiple concentrations spanning a range from well below to well above Kd. At each concentration, the amount of radioligand specifically bound to receptor is measured. As radioligand concentration increases, binding approaches a maximum (saturation) because all receptor binding sites become occupied. The Scatchard analysis (or non-linear regression) of this saturation binding data yields two parameters: Bmax, the maximum binding capacity representing total receptor density (expressed as fmol/mg protein or similar units), and Kd, the equilibrium dissociation constant representing receptor affinity. Bmax is determined by the plateau of the saturation curve, and Kd is the radioligand concentration at which 50% of Bmax is achieved. These are purely binding parameters -- they describe receptor number and affinity but say nothing directly about functional pharmacodynamic effect.
Option A: Option A is incorrect -- EC50 and Emax are functional pharmacodynamic parameters measured in bioassays; they cannot be determined from binding data alone without knowledge of the stimulus-response relationship.
Option C: Option C is incorrect -- association and dissociation rate constants (kon and koff) are measured by kinetic binding assays, not saturation assays; Kd equals koff/kon but the individual rate constants require separate experimental approaches.
Option D: Option D is incorrect -- intrinsic efficacy and functional potency cannot be determined from binding data alone; a drug's binding affinity tells us nothing about what happens after binding.
Option E: Option E is incorrect -- receptor reserve and Hill coefficient require functional pharmacodynamic experiments, not binding assays; Scatchard analysis does not yield these parameters.
6. Which of the following correctly identifies the scholar credited with introducing the concept of "efficacy" as a property distinct from binding affinity in pharmacology?
A) Stephenson, whose 1956 modification of occupancy theory introduced efficacy as the capacity of a drug to activate a receptor once bound -- distinct from affinity, which determines how well a drug binds; this framework explained why partial agonists bind receptors with high affinity yet produce submaximal responses regardless of concentration
B) Langley, who proposed the existence of a "receptive substance" at the neuromuscular junction in the early twentieth century based on observations that nicotine and curare produced opposing effects at the same site
C) Ehrlich, whose side-chain theory established the conceptual basis for selective pharmacological targeting and introduced the lock-and-key metaphor for drug-receptor interaction
D) Clark, whose 1926 quantitative work established that biological effect is proportional to receptor occupancy and derived the first mathematical framework for concentration-effect relationships
E) Furchgott, who quantified receptor reserve by using irreversible antagonists to progressively inactivate receptor populations and demonstrated that maximum effect can be achieved at sub-saturating agonist concentrations
ANSWER: A
Rationale:
Robert P. Stephenson's 1956 paper "A modification of receptor theory" is one of the most important publications in the history of pharmacodynamics. Stephenson recognized that Clark's original occupancy theory -- which proposed that drug effect is directly proportional to the fraction of receptors occupied -- could not explain the behavior of partial agonists. Partial agonists bind receptors but produce submaximal effects even at concentrations that saturate all available receptors. Stephenson resolved this by introducing the concept of efficacy (he used the symbol e) as an intrinsic property of the drug-receptor complex that determines how effectively receptor occupancy is translated into biological stimulus. A full agonist has high efficacy; a partial agonist has intermediate efficacy; an antagonist has zero efficacy. This framework separated binding (described by affinity) from activation (described by efficacy), providing the conceptual foundation for understanding partial agonists, inverse agonists, and the operational model of agonism that followed.
Option B: Option B is incorrect -- Langley established the receptor concept and coined the term "receptive substance" but did not introduce efficacy; his contributions preceded Stephenson by 50 years.
Option C: Option C is incorrect -- Ehrlich's side-chain theory was a conceptual contribution to selective drug action, not a formalization of efficacy as a pharmacodynamic parameter.
Option D: Option D is incorrect -- Clark established quantitative occupancy theory and the concentration-effect relationship, but his framework assumed that effect was linearly proportional to occupancy; it was Stephenson who identified the need for an additional parameter (efficacy) to explain deviations from Clark's predictions.
Option E: Option E is incorrect -- Furchgott's contribution was the receptor reserve concept and the operational method for quantifying it, not the introduction of efficacy as a concept.
7. Which of the following drugs is classified as an irreversible acetylcholinesterase (AChE) inhibitor?
A) Neostigmine, which reversibly inhibits AChE through carbamylation of the active-site serine and is used to reverse non-depolarizing neuromuscular blockade
B) Pyridostigmine, which reversibly inhibits AChE and is the primary therapy for myasthenia gravis due to its oral bioavailability and intermediate duration of action
C) Edrophonium, which reversibly inhibits AChE through electrostatic interaction with the anionic site and has an extremely short duration of action of 5-10 minutes
D) Organophosphate nerve agents such as sarin and VX (a persistent organophosphate nerve agent), which irreversibly phosphorylate the active-site serine residue of AChE, permanently inactivating the enzyme; clinical recovery requires synthesis of new AChE over days to weeks, or can be accelerated by pralidoxime (2-PAM) if administered before aging of the phosphorylated enzyme occurs
E) Donepezil, which reversibly inhibits AChE in the CNS through non-covalent binding and is used in Alzheimer's disease management; its selectivity for CNS AChE over peripheral AChE reduces cholinergic side effects
ANSWER: D
Rationale:
Organophosphate compounds including nerve agents (sarin, VX, tabun, novichok agents) and some pesticides (parathion, malathion) are irreversible AChE inhibitors. They react with the active-site serine residue (Ser203 in human AChE) through phosphylation -- forming a covalent phosphoserine adduct. Unlike the carbamylation produced by neostigmine and pyridostigmine (which hydrolyzes spontaneously within minutes to hours), organophosphate phosphylation is stable and does not hydrolyze spontaneously at a clinically useful rate. The phosphorylated enzyme undergoes a time-dependent process called aging, in which an alkyl group is lost from the phosphate adduct, rendering the modification completely irreversible and resistant to reactivation by pralidoxime. Before aging occurs (the window varies by agent, from minutes for soman to hours for sarin), pralidoxime can nucleophilically attack the phosphorus and regenerate active AChE. The clinical consequence of irreversible AChE inhibition is accumulation of acetylcholine at all cholinergic synapses, producing the SLUDGE syndrome (salivation, lacrimation, urination, defecation, GI distress, emesis) plus bradycardia and the risk of respiratory failure. Options A, B, and C are incorrect -- neostigmine, pyridostigmine, and edrophonium are all reversible AChE inhibitors; their inhibition is temporary and clinically useful precisely because of its reversibility.
Option E: Option E is incorrect -- donepezil is a reversible AChE inhibitor that binds through non-covalent interactions; it has no covalent modification of the enzyme.
8. The term "biophase" in pharmacodynamics refers to which of the following?
A) The plasma compartment, where free drug concentration is measured for pharmacokinetic modeling and is assumed to be in rapid equilibrium with the tissue site of drug action
B) The intracellular second messenger system activated downstream of receptor occupancy, including cyclic nucleotides, protein kinases, and transcription factors that transduce the receptor signal into biological response
C) The phase of drug metabolism during which prodrugs are converted to their pharmacologically active form, typically by hepatic enzymes, prior to distribution to the site of action
D) The compartment into which a drug distributes during the distribution phase of a two-compartment pharmacokinetic model, representing peripheral tissues such as muscle and adipose
E) The tissue or fluid compartment immediately surrounding the receptor -- the site-of-action microenvironment where drug concentration directly determines the extent of receptor occupancy; drug concentration in the biophase may differ substantially from plasma concentration, explaining temporal delays between plasma drug levels and pharmacological effect
ANSWER: E
Rationale:
The biophase (also called the effect site or effect compartment) is the microenvironment immediately surrounding the drug's receptor -- the local concentration of drug at this site determines the degree of receptor occupancy and therefore the pharmacological effect. The biophase concentration may differ from plasma concentration for several reasons: the drug may need to cross a membrane barrier (such as the blood-brain barrier for CNS drugs), distribute through tissue, or achieve equilibration in a compartment with restricted access. This is why plasma drug concentration and pharmacological effect do not always track in parallel -- the plasma is sampled, but it is the biophase that drives the pharmacodynamic response. The effect compartment model mathematically links plasma concentration to biophase concentration through a first-order rate constant (ke0), allowing prediction of the time course of pharmacological effect from measured plasma concentrations. The concept of biophase is essential to understanding phenomena such as the counterclockwise hysteresis seen with morphine (slow CNS equilibration) and the 2-hour offset of inhalational anesthetics from adipose tissue.
Option A: Option A is incorrect -- the plasma compartment is not the biophase; it is where drug concentration is typically measured, but it may not reflect drug concentration at the receptor site, particularly when distributional delays are present.
Option B: Option B is incorrect -- second messenger systems are downstream of receptor occupancy; the biophase is defined by its proximity to the receptor, not by the intracellular signaling cascades that follow receptor activation.
Option C: Option C is incorrect -- prodrug bioactivation is a pharmacokinetic process, not a pharmacodynamic concept; the biophase refers to drug distribution to the receptor site, not to metabolic conversion.
Option D: Option D is incorrect -- the peripheral compartment in a two-compartment pharmacokinetic model describes drug distribution to muscle and fat, which is a pharmacokinetic concept; the biophase is a pharmacodynamic concept describing the drug concentration at the receptor.
ANSWER KEY: Q1=D Q2=A Q3=E Q4=C Q5=B Q6=A Q7=D Q8=E
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.